Cargando…

Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling

Most studies focus on how intestinal microbiota influence cancer immunotherapy through activating gut immunity. However, immunotherapies related to innate responses such as CD47 blockade rely on the rapid immune responses within the tumor microenvironment. Using one defined anaerobic gut microbiota...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Yaoyao, Zheng, Wenxin, Yang, Kaiting, Harris, Katharine G., Ni, Kaiyuan, Xue, Lai, Lin, Wenbin, Chang, Eugene B., Weichselbaum, Ralph R., Fu, Yang-Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Rockefeller University Press 2020
Materias:	Brief Definitive Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201921/ https://www.ncbi.nlm.nih.gov/pubmed/32142585 http://dx.doi.org/10.1084/jem.20192282

Ejemplares similares

Suppression of local type I interferon by gut microbiota–derived butyrate impairs antitumor effects of ionizing radiation
por: Yang, Kaiting, et al.
Publicado: (2021)

CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes
por: Kosaka, Akemi, et al.
Publicado: (2021)

Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
por: Jiang, Xiaoyi, et al.
Publicado: (2022)

Correction: Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
Publicado: (2022)

Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade
por: Si, Wei, et al.
Publicado: (2022)

Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling
por: Lepelley, Alice, et al.
Publicado: (2020)

Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis
por: Kim, Jungsu, et al.
Publicado: (2012)

Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy
por: Ni, Kaiyuan, et al.
Publicado: (2018)

Cd47 Ligation Selectively Downregulates Human Interleukin 12 Production
por: Armant, Myriam, et al.
Publicado: (1999)

Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection
por: vom Berg, Johannes, et al.
Publicado: (2013)

A defect in COPI-mediated transport of STING causes immune dysregulation in COPA syndrome
por: Deng, Zimu, et al.
Publicado: (2020)

Intratumoral injection of STING ligand promotes abscopal effect
por: Baird, Jason R, et al.
Publicado: (2014)

Enhanced cGAS-STING–dependent interferon signaling associated with mutations in ATAD3A
por: Lepelley, Alice, et al.
Publicado: (2021)

Host STING-dependent MDSC mobilization drives extrinsic radiation resistance
por: Liang, Hua, et al.
Publicado: (2017)

CCL28 Controls Immunoglobulin (Ig)A Plasma Cell Accumulation in the Lactating Mammary Gland and IgA Antibody Transfer to the Neonate
por: Wilson, Eric, et al.
Publicado: (2004)

STING activation in cancer immunotherapy
por: Su, Ting, et al.
Publicado: (2019)

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells
por: Zhang, Bin, et al.
Publicado: (2007)

The confluence of radiotherapy and immunotherapy
por: Burnette, Byron, et al.
Publicado: (2012)

Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma
por: Boudreau, C. Elizabeth, et al.
Publicado: (2021)

Cd47 (Integrin-Associated Protein) Engagement of Dendritic Cell and Macrophage Counterreceptors Is Required to Prevent the Clearance of Donor Lymphohematopoietic Cells
por: Blazar, Bruce R., et al.
Publicado: (2001)

Intratumoral Immunotherapy—Update 2019
por: Hamid, Omid, et al.
Publicado: (2019)

Trial watch: intratumoral immunotherapy
por: Humeau, Juliette, et al.
Publicado: (2021)

Immunotherapeutic Agents for Intratumoral Immunotherapy
por: Shyr, Chih-Rong, et al.
Publicado: (2023)

Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model
por: Zaidi, Ali H., et al.
Publicado: (2021)

Inflammatory Cytokine Profiles During Exercise in Obese, Diabetic, and Healthy Children
por: Galassetti, Pietro R., et al.
Publicado: (2011)

Complementary and Alternative Medicine in Children with Type 1 Diabetes Mellitus
por: Haliloglu, Belma, et al.
Publicado: (2011)

3M Syndrome: A Report of Four Cases in Two Families
por: Güven, Ayla, et al.
Publicado: (2011)

Nanoscale metal-organic frameworks for x-ray activated in situ cancer vaccination
por: Ni, Kaiyuan, et al.
Publicado: (2020)

Leukotriene B(4) amplifies eosinophil accumulation in response to nematodes
por: Patnode, Michael L., et al.
Publicado: (2014)

Biomimetic nanoscale metal–organic framework harnesses hypoxia for effective cancer radiotherapy and immunotherapy
por: Ni, Kaiyuan, et al.
Publicado: (2020)

A STING-Activating Nanovaccine for Cancer Immunotherapy
por: Luo, Min, et al.
Publicado: (2017)

Intratumoral TNFα improves immunotherapy
por: Johansson, Anna, et al.
Publicado: (2012)

Characterization of intratumor microbiome in cancer immunotherapy
por: Zhang, Zhao, et al.
Publicado: (2023)

Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
por: Duan, Xiaopin, et al.
Publicado: (2019)

Human KIT(+) myeloid cells facilitate visceral metastasis by melanoma
por: Yu, Chun I., et al.
Publicado: (2021)

Intratumoral synthesis of transformable metal-phenolic nanoaggregates with enhanced tumor penetration and retention for photothermal immunotherapy
por: He, Xianglian, et al.
Publicado: (2022)

cGAS-STING Pathway as the Target of Immunotherapy for Lung Cancer
por: Dan, Qinfu, et al.
Publicado: (2023)

Chronic T cell proliferation in brains after stroke could interfere with the efficacy of immunotherapies
por: Heindl, Steffanie, et al.
Publicado: (2021)

Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels
por: Pflicke, Holger, et al.
Publicado: (2009)

Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy
por: Xu, Meng Michelle, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rmoh4peqj657ak9p0trr963nqf